Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Titan Pharmaceuticals Inc TTNP

Healthcare
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The... see more

Recent & Breaking News (NDAQ:TTNP)

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

GlobeNewswire January 25, 2024

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

GlobeNewswire December 28, 2023

Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

GlobeNewswire October 16, 2023

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

GlobeNewswire September 18, 2023

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

GlobeNewswire July 27, 2023

Titan Pharmaceuticals Provides Shareholder Update

GlobeNewswire December 15, 2022

UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

GlobeNewswire December 12, 2022

Titan Pharmaceuticals Announces Board Expansion and Management Changes

PR Newswire August 16, 2022

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

PR Newswire July 5, 2022

Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market

PR Newswire February 2, 2022

Titan Pharmaceuticals to Explore Strategic Alternatives

PR Newswire December 21, 2021

Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

PR Newswire November 8, 2021

Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

PR Newswire November 5, 2021

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

PR Newswire October 25, 2021

Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

PR Newswire October 12, 2021

Titan Pharmaceuticals Partners With Molteni To Market Probuphine® In Europe

PR Newswire November 28, 2017

European Medicines Agency Accepts Titan Pharmaceuticals' Marketing Authorization Application For Probuphine®

PR Newswire November 27, 2017

Titan Pharmaceuticals, Inc. to Host Earnings Call

Accesswire November 9, 2017

Titan Pharmaceuticals Reports Third Quarter 2017 Financial Results

PR Newswire November 9, 2017

Titan Pharmaceuticals Schedules Conference Call To Review Third Quarter 2017 Financial Results

PR Newswire November 3, 2017